story of the week
Mosunetuzumab for Relapsed or Refractory Follicular Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lancet Oncol 2022 Jul 05;[EPub Ahead of Print], LE Budde, LH Sehn, M Matasar, SJ Schuster, S Assouline, P Giri, J Kuruvilla, M Canales, S Dietrich, K Fay, M Ku, L Nastoupil, CY Cheah, MC Wei, S Yin, CC Li, H Huang, A Kwan, E Penuel, NL BartlettFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.